Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Harvard Business School
QuintilesIMS
Boehringer Ingelheim
Deloitte
Daiichi Sankyo
UBS
Moodys

Generated: December 18, 2018

DrugPatentWatch Database Preview

Santarus Inc Company Profile

« Back to Dashboard

Summary for Santarus Inc
International Patents:80
US Patents:8
Tradenames:3
Ingredients:3
NDAs:4
Patent Litigation for Santarus Inc: See patent lawsuits for Santarus Inc

Drugs and US Patents for Santarus Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No 8,481,078 ➤ Sign Up Y ➤ Sign Up
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-001 Jun 15, 2004 AB RX Yes No ➤ Sign Up ➤ Sign Up
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes 7,658,944 ➤ Sign Up Y ➤ Sign Up
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 AB RX Yes Yes 9,173,847 ➤ Sign Up Y ➤ Sign Up
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No 9,173,847 ➤ Sign Up Y ➤ Sign Up
Santarus Inc FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 AB RX Yes No 7,658,944 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Santarus Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Santarus Inc GLUMETZA metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021748-002 Jun 3, 2005 6,635,280 ➤ Sign Up
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-001 Jun 15, 2004 6,489,346 ➤ Sign Up
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 6,489,346 ➤ Sign Up
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 RE45198 ➤ Sign Up
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-001 Jun 15, 2004 7,399,772 ➤ Sign Up
Santarus Inc ZEGERID omeprazole; sodium bicarbonate CAPSULE;ORAL 021849-002 Feb 27, 2006 6,489,346 ➤ Sign Up
Santarus Inc ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-001 Jun 15, 2004 5,840,737 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SANTARUS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 20 mg/1100 mg and 40 mg/1100 mg ➤ Subscribe 2007-04-30
➤ Subscribe Powder for Oral Suspension 20mg/1680mg per packet ➤ Subscribe 2007-11-13
➤ Subscribe Tablets 40 mg and 120 mg ➤ Subscribe 2010-03-17
➤ Subscribe Powder for Oral Suspension 40 mg/1680 mg per packet ➤ Subscribe 2007-08-24
➤ Subscribe Extended-release Tablets 500 mg and 1000 mg ➤ Subscribe 2009-07-27

Supplementary Protection Certificates for Santarus Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000071 Germany ➤ Sign Up PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
C/GB11/015 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0677 Netherlands ➤ Sign Up PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
2012022 Lithuania ➤ Sign Up PRODUCT NAME: LINAGLIPTINUM + METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/12/780/001 - EU/1/12/780/034 20120720
2008013 Lithuania ➤ Sign Up PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
2008013,C1412357 Lithuania ➤ Sign Up PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
2014000070 Germany ➤ Sign Up PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
QuintilesIMS
AstraZeneca
Queensland Health
Chinese Patent Office
Johnson and Johnson
McKinsey
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.